Trial · NCT00000392
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
NCT00000392, Phase 2, Completed, National Institute of Mental Health (NIMH); results first posted 2015-08-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment. Trials, record NCT00000392. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000392
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
- NCT number
- NCT00000392
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 215 participants, actual
- Lead sponsor
- National Institute of Mental Health (NIMH)
- Conditions
- HIV Infections, Cognition Disorders
- Interventions
- Peptide T, Placebo
- First posted
- 2000-01-18
- Last updated
- 2017-02-28
- Results first posted
- 2015-08-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Global Neurocognitive Performance z Score From Baseline | Baseline and 6 months | Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP) |
| Secondary | Change in Neurocognitive Performance Domain z Scores From Baseline | Baseline and 6 months | Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Global Neurocognitive Performance z Score From Baseline | Baseline and 6 months | z score | MEAN | |
| SECONDARY | Change in Neurocognitive Performance Domain z Scores From Baseline | Baseline and 6 months | z score | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Global Neurocognitive Performance z Score From Baseline | Peptide T | 0.24 | Standard Error 0.05 | z score | |
| Change in Global Neurocognitive Performance z Score From Baseline | Placebo | 0.16 | Standard Error 0.03 | z score | |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Peptide T | Verbal fluency | 0.14 | Standard Error 0.09 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Placebo | Verbal fluency | 0.15 | Standard Error 0.08 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Peptide T | Visuospatial ability | 0.17 | Standard Error 0.06 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Placebo | Visuospatial ability | 0.25 | Standard Error 0.06 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Peptide T | Abstract thinking | 0.34 | Standard Error 0.07 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Placebo | Abstract thinking | 0.23 | Standard Error 0.04 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Peptide T | Speed of information processing | 0.23 | Standard Error 0.07 | z score |
| Change in Neurocognitive Performance Domain z Scores From Baseline | Placebo | Speed of information processing | 0.14 | Standard Error 0.05 | z score |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Peptide T | 106 | |
| Overall Study | STARTED | Placebo | 109 | |
| Overall Study | COMPLETED | Peptide T | 66 | |
| Overall Study | COMPLETED | Placebo | 77 | |
| Overall Study | NOT COMPLETED | Peptide T | 40 | |
| Overall Study | NOT COMPLETED | Placebo | 32 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Depression or Irritability | Psychiatric disorders | Peptide T | 7 | 106 | |
| other | Depression or Irritability | Psychiatric disorders | Placebo | 1 | 109 | |
| other | Rash | Skin and subcutaneous tissue disorders | Peptide T | 34 | 106 | |
| other | Rash | Skin and subcutaneous tissue disorders | Placebo | 42 | 109 | |
| other | Nasal Congestion | Respiratory, thoracic and mediastinal disorders | Peptide T | 12 | 106 | |
| other | Nasal Congestion | Respiratory, thoracic and mediastinal disorders | Placebo | 5 | 109 | |
| other | Proteinuria | Renal and urinary disorders | Peptide T | 18 | 106 | |
| other | Proteinuria | Renal and urinary disorders | Placebo | 9 | 109 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Peptide T | 4 | 106 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Placebo | 0 | 109 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Peptide T | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Peptide T | 75 | 106 |
| Total, other adverse events | Placebo | 57 | 109 |
| Total, serious adverse events | Peptide T | 8 | 106 |
| Total, serious adverse events | Placebo | 3 | 109 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 9443710 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Peptide T vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000392
GET https://conductscience.org/api/trials/v1/NCT00000392/registered